: Characteristics of untreated groups from preoperative evaluation of morbidly obese subjects Untreated diabetic subjects at the time of surgery were compared with two groups of non-diabetic morbidly obese subjects defined by median value of fasting blood-glucose concentration ([G]: above (n=14) or below (n=14) 5.31 mmol.L -1 ). Values are presented as mean ± SEM. HOMA-IR mean values were calculated from blood-glucose and plasma-insulin concentration (glucose (mmol.L -1 ) X insulin (mU.L -1 ) / 22.5, homeostatic model assessment). Untreated diabetic obese subjects (n=7) were free of diabetes 6 months after surgery. Kruskal-Wallis statistical test was between untreated diabetic and all non-diabetic subjects.
[G] <5.31
[G]≥5.31
Untreated diabetes [G]≥7.0 P Number of subjects (n) 14 14 7 Age of surgery (years) 38.8 ± 3.4 41.9 ± 3.3 50.1 ± 3.4 0.14 Weight (kg) 124.8 ± 4.5 146.3 ± 7.9 130.2 ± 7.1 0.09 BMI (kg.m -2 ) 47.7 ± 2 51.6 ± 2.5 46 ± 1.9 0.34 Blood glucose (mmol.L -1 ) 4.7 ± 0.1 5.8 ± 0.2 7.5 ± 0.6 6×10 -6
Plasma insulin (mU.L -1 ) 11.4 ± 1.5 14.1 ± 1.7 14.8 ± 2.6 0.47 HOMA-IR 2.4 ± 0.4 3.8 ± 0.6 4.8 ± 0.8 0.004 HbA1c (%) 5.5 ± 0.1 5.8 ± 0.1 6.5 ± 3.4 0.01
Supplementary Diabetes duration (years) 9 ± 2.1 7.1 ± 1.9 6.8 ± 1.7 13.3 ± 9.5 0.33 0.95
Age of diabetes start (years) 43.4 ± 2.2 40.4 ± 2.8 44.9 ± 3.3 39 ± 10.7 0.91 0.24
Blood glucose (mmol.L-1) 6.6 ± 0.8 7.3 ± 0.5 6.9 ± 0.7 8 ± 2 0.74 0.56
14.9 ± 2.2 14.2 ± 1.4 15.3 ± 3.7 9.6 ± 0. Insulin/Metformin ± OAD (n=8 CTER (a,d,g ) and N-terminal (hGLUT2 X-loop-GWG ) antibody (b,e,h). Only merged images (c,f,i) give the full picture of GLUT2 location. Images a, b, c are representative of 7 (100%) lean subjects, Images d,e,f of 8 (13%) and g,h,i of 30 (76%) obese subjects respectively.
Supplementary Figure 2. Intracellular GLUT2 visualized using antibodies to various epitopes
Representative confocal microscopy images performed as in Figure 1 showing GLUT2 accumulated in endosomes with 2 N-terminal (hGLUT2 X-loop1-GWG and hmrGLUT2 X-loop1-GLK ; a, b; scale 10 µm) antibodies and a C-terminal (hGLUT2 CTER ; c,d; scale 100 µm) antibody. Note that endosomal accumulation of GLUT2 is observed from tip (c) to crypt (d) cells.
Supplementary Figure 3. Identification of the intracellular compartment accumulating GLUT2 in obese subjects
Representative confocal microscopy images performed in jejunal samples from obese subjects exhibiting GLUT2 accumulated above the nucleus. Immunolocalizations were performed in parallel (scale in µm, white bars). GLUT2 above the nucleus colocated with the endosomal marker EEA1 (hGLUT2 CTER /EEA1, a) but not with the lysosome marker Lamp1 (hGLUT2 CTER /Lamp1, b) nor with endoplasmic reticulum markers BIP/GRP78 or PDI (hGLUT2 CTER /GRP78/BiP, c; or hGLUT2 CTER /PDI, d). Split images for each antibody pair are provided below.
